Clare Daly (Dublin Fingal, Independent)
Link to this: Individually | In context | Oireachtas source

471. To ask the Minister for Health if funding for a life-saving treatment for persons with spinal muscular atrophy, Spinraza, will be approved in line with the BeNeLuxA initiative (details supplied); and if he will make a statement on the matter. [37349/18]

Mick Wallace (Wexford, Independent)
Link to this: Individually | In context | Oireachtas source

474. To ask the Minister for Health if the drug Spinraza will be reimbursed or made available to sufferers of spinal muscular atrophy as has been successfully negotiated by other BeNeLuxA countries; and if he will make a statement on the matter. [37355/18]

Tommy Broughan (Dublin Bay North, Independent)
Link to this: Individually | In context | Oireachtas source

501. To ask the Minister for Health when Spinraza, the treatment for spinal muscular atrophy, will be available here in view of the fact that it is available to other members of the BeNeLuxA initiative; and if he will make a statement on the matter. [37460/18]

Simon Harris (Wicklow, Fine Gael)
Link to this: Individually | In context | Oireachtas source

I propose to take Questions Nos. 471, 474 and 501 together.

The HSE has statutory responsibility for medicine pricing and reimbursement decisions, in accordance with the Health (Pricing and Supply of Medical Goods) Act 2013. The Act specifies the criteria for decisions on the reimbursement of medicines.

HSE decisions on which medicines are reimbursed by the taxpayer are made on objective, scientific and economic grounds, on the advice of the National Centre for Pharmacoeconomics (NCPE). The NCPE conducts health technology assessments (HTAs) for the HSE and makes recommendations on reimbursement to assist HSE decisions.

The HSE strives to reach a decision in as timely a manner as possible. However, because of the significant monies involved, it must ensure that the best price is achieved, as these commitments are often multi-million euro investments on an on-going basis. This can lead to a protracted deliberation process.

Nusinersen (Spinraza) is for the treatment of 5q spinal muscular atrophy (SMA).

An application for the reimbursement of Nusinersen (Spinraza) is currently being processed by the HSE. No decision has been arrived at as yet as the statutory assessment process is still ongoing.

Two members of the Beneluxa Initiative (Belgium and the Netherlands) completed a joint negotiation for the reimbursement of Spinraza in July 2018. This process began before Ireland joined the collaboration and Ireland was not party to these negotiations.